Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature
- 109 Downloads
Nimotuzumab is an IgG1 antibody that targets epidermal growth factor receptor (EGFR). Overexpression of EGFR is detected in some pediatric brain tumors including diffuse intrinsic pontine gliomas (DIPG)s.
Since May 2010, nimotuzumab, combined with carboplatin or vinorelbine or Temozolomide (TMZ), was administered during progressive disease (PD) after the use of the institutional protocol consisting of radiotherapy (RT) + TMZ and adjuvant TMZ. After May 2012, children with newly diagnosed disease received TMZ during RT, and nimotuzumab and TMZ after RT. Nimotuzumab was given as 150 mg/m2/dose once a week for 12 weeks, and then every other week with TMZ until PD. PD patients were switched to nimotuzumab + vinorelbine combination until death.
Nimotuzumab was used in 24 children with DIPG (seven in the PD group, 17 in the newly diagnosed patient group). In the PD group, median survival time was 12 months (7–42 months); 1-year and 2-year overall survival (OS) rates were 42.9 ± 18% and 14.3 ± 13%, respectively. The median survival in this group, after the initiation of nimotuzumab was 6 months (3–8 months). In the newly diagnosed patient group, median survival time was 11 months (3–35 months) and median progression free survival was 4 months (1–21 months). The 1-year OS in this group was 35.3 ± 11% and 2 year OS was 11.8 ± 7%. Nimotuzumab ± chemotherapy was well tolerated with no major adverse effect.
Nimotuzumab-containing regimens are feasible and tolerable; it might be that some patients either with newly diagnosed DIPG or with progressive disease may benefit modestly from nimotuzumab-containing combinations.
KeywordsAnti-epidermal growth factor receptor antibody Diffuse pontine glioma Child Treatment
We thank Prof Dr. Serra Sencer and Prof Dr. Kubilay Aydın, from the Istanbul University, Istanbul Medical Faculty, Department of Radiology, for the radiologic evaluation.
Compliance with ethical standards
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
- 6.Gilbertson RJ, Hill DA, Hernan R (2003) ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem gliomas. Clin Cancer Res 9:3620–3624Google Scholar
- 7.Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, Bouffet E, Hawkins C (2010) Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADPribose) polymerase as potential therapeutic targets. J Clin Oncol 28:1337–1344CrossRefGoogle Scholar
- 9.Bode U, Buchen S, Warmuth-Metz M, Pietsch T, Bach F, Fleischhack G (2007) Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents [abstract]. J Clin Oncol 25 Suppl. 2006Google Scholar
- 10.Bode U, Windelberg M, Massimino M et al (2008) Phase III trial of nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents [abstract]. J Clin Oncol 26.Suppl.2008Google Scholar
- 12.Massimino M, Biassoni V, Miceli R et al (2014) Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neuro-Oncol 118:305–312Google Scholar
- 13.National Cancer Institute. Common terminology criteria for adverse events v4.03 (CTCAE). June 14, 2010. Available at evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
- 15.Bartels U, Wolff J, Gore L, Dunkel I, Gilheeney S, Allen J, Goldman S, Yalon M, Packer RJ, Korones DN, Smith A, Cohen K, Kuttesch J, Strother D, Baruchel S, Gammon J, Kowalski M, Bouffet E (2014) Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsicpontine glioma. Neuro-Oncology 16:1554–1559CrossRefGoogle Scholar
- 17.Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N et al (2018) Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG registries. J Clin Oncol 36(19):1963–1972CrossRefGoogle Scholar
- 18.Janssens GO, Gandola L, Bolle S, Mandeville H, Ramos-Albiac M, van Beek K, Benghiat H, Hoeben B, Morales la Madrid A, Kortmann RD, Hargrave D, Menten J, Pecori E, Biassoni V, von Bueren AO, van Vuurden DG, Massimino M, Sturm D, Peters M, Kramm CM (2017) Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer 73:38–47CrossRefGoogle Scholar
- 20.Walker DA, Liu J, Kieran M, Jabado N, Picton S, Packer R, St. Rose C, (on behalf of the CPN Paris 2011 Conference Consensus Group), van Meeteren AS, Carvalho A, van Damme A, Depreitere B, Gustavsson B, Due Tonnessen BJ, Bertozzi-Salamon AI, Brentrup A, Raybaud C, Jones C, Dufour C, Dorfer C, Sainte-Rose C, Malluci C, Hargrave D, Walker D, van Vuurden D, de Carli E, Bouffet E, van Calenbergh F, Frappaz D, Frassanito P, Goodrich J, Baechli H, Grill J, Ternier J, Cappelen J, Caird J, Pereira J, Riffaud L, Baroncini M, Walker M, Kieran M, Ozek M, Jabado N, Nysom K, Varlet P, Goodden J, Bertolini P, Perilongo G, Mercier P, Grundy R, Kortmann RD, Packer R, Pfister S, Constantini S, Sgouros S, Holm S, Czech T, Merchant T, Stokland T, Ridola V, Vandertop P (2013) A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro-Oncology 15(4):462–468CrossRefGoogle Scholar